| 37.91 0.9 (2.43%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 44.61  |
1-year : | 52.11 |
| Resists | First : | 38.2 |
Second : | 44.61 |
| Pivot price | 34.51 |
|||
| Supports | First : | 28.75 |
Second : | 22.91 |
| MAs | MA(5) : | 37.25 |
MA(20) : | 32.32 |
| MA(100) : | 23.68 |
MA(250) : | 0 | |
| MACD | MACD : | 2.7 |
Signal : | 2.3 |
| %K %D | K(14,3) : | 97.8 |
D(3) : | 96 |
| RSI | RSI(14): 71.4 |
|||
| 52-week | High : | 38.2 | Low : | 13.19 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ VTVT ] has closed below upper band by 19.3%. Bollinger Bands are 63.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 35 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 38.23 - 38.42 | 38.42 - 38.55 |
| Low: | 36.42 - 36.68 | 36.68 - 36.84 |
| Close: | 37.54 - 37.93 | 37.93 - 38.18 |
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
Wed, 24 Dec 2025
vTv Therapeutics (VTVT) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Sat, 20 Dec 2025
HC Wainwright & Co. Raises Price Target for VTVT to $47 | VTVT S - GuruFocus
Fri, 19 Dec 2025
HC Wainwright & Co. Maintains vTv Therapeutics (VTVT) Buy Recommendation - Nasdaq
Fri, 19 Dec 2025
We're Interested To See How vTv Therapeutics (NASDAQ:VTVT) Uses Its Cash Hoard To Grow - Yahoo Finance
Thu, 18 Dec 2025
vTv Therapeutics Announces Phase 2 Clinical Study for Cadisegliatin in Type 2 Diabetes in Collaboration with M42’s IROS - Quiver Quantitative
Thu, 18 Dec 2025
Year-long trial will test a new pill to help people on insulin control diabetes - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 2.9e+006 (%) |
| Held by Institutions | 23.6 (%) |
| Shares Short | 19 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.978e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -175 % |
| Return on Assets (ttm) | 382.3 % |
| Return on Equity (ttm) | -26.2 % |
| Qtrly Rev. Growth | 17000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -128.34 |
| EBITDA (p.s.) | -3.234e+007 |
| Qtrly Earnings Growth | -3.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.3 |
| Price to Cash Flow | 3.33 |
| Dividend | 0 |
| Forward Dividend | 19140 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|